Search is Powered by Google
Breast Cancer News

Breast, Ovarian Cancer Prediction Models More Accurate For White Women Than Asian-American Women, Study Finds

Main Category: Breast Cancer
Also Included In: Ovarian Cancer;  IT / Internet / E-mail;  Public Health
Article Date: 26 Sep 2008 - 7:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Two widely used prediction models for identifying a woman's risk for breast and ovarian cancer appear to be less reliable for Asian-American women compared with white women, according to a study in the October issue of the Journal of Clinical Oncology, Reuters Health reports.

For the study, lead researcher Allison Kurian of Stanford University and colleagues evaluated the effectiveness of two prediction models, known as BRCAPRO and Myriad II, in 200 Asian-American participants and 200 white participants. The models, which are available at no cost through the Internet, use a woman's personal and family history of breast and ovarian cancers to predict their risk for the cancers. The models are considered to have a generally good performance and are used to help determine whether a woman should undergo further testing, Reuters Health reports.

Both models accurately predicted the number of white women with mutations in two genes -- BRCA1 and BRCA2 -- that are commonly associated with an increased risk for breast and ovarian cancers. According to the study, 25 white women were found to have the mutations; BRCAPRO predicted 24 and Myriad II predicted 25.

The models, however, underreported the number of Asian-American women with the mutations. While 49 Asian-American women were found to have a mutation, BRCAPRO predicted mutations only for 25 and Myriad II predicted mutations for 26 of the women.

Kurian said, "Our findings indicate that Asian-American women with BRCA mutations may not be referred for genetic testing as often as they should be." Further research is needed to better understand the racial differences in BCRA mutations, researchers said (Reuters Health, 9/24).

An abstract of the study is available online.

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

customize your homepage

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

Breast Cancer Treatment: Get Involved image Breast Cancer Treatment: Get Involved

Today, breast cancer patients may be treated by a multidisciplinary team of specialists, consisting of nurses, oncologists, surgeons, social workers, nutritionists and genetic counselors. However, patients, too, have a critical role in their treatment...

View more videos...